跳转至内容
Merck
CN

主要文件

查看所有文档

SML2259

拉帕替尼

≥98% (HPLC), EGFR/ErbB1 and HER2/ErbB2 inhibitor, powder

别名:

拉帕替尼, GD 2016, GSK 572016, GW-572016, GW572016, N-（3-氯-4-（（3-氟苯基）甲氧基）苯基）-6-（5-（（2-甲基磺酰基乙基氨基）甲基）-2-呋喃基）喹唑啉-4-胺, N-（3-氯-4-（（3-氟苯基）甲氧基）苯基）-6-（5-（（（（2-（甲基磺酰基）乙基）氨基）甲基）-2-呋喃基）-4-喹唑啉胺

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C29H26ClFN4O4S
化学文摘社编号:
231277-92-2
分子量:
581.06
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
MFCD09264194
Assay:
≥98% (HPLC)
Form:
powder
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

拉帕替尼, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChI key

BCFGMOOMADDAQU-UHFFFAOYSA-N

Gene Information

human ... EGFR(1956), ERBB2(2064)

Biochem/physiol Actions

拉帕替尼(lapatinb)是针对表皮生长因子受体(EGFR/ErbB1)和人表皮生长因子受体2(HER2/ErbB2)的双酪氨酸激酶抑制剂。它与三磷酸腺苷(ATP)竞争酪氨酸激酶结构域上的结合位点。已有研究表明拉帕替尼参与乳腺、肺、外阴、胃和头颈癌等多种人癌细胞中的体外生长抑制和凋亡诱导。

Still not finding the right product?

Explore all of our products under 拉帕替尼

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lapatinib in breast cancer
Bilancia D, et al.
Annals of Oncology, 18, vi26-vi30 (2007)
Sharad Verma et al.
PloS one, 13(2), e0190942-e0190942 (2018-02-02)
HER-2 belongs to the human epidermal growth factor receptor (HER) family. Via different signal transduction pathways, HER-2 regulates normal cell proliferation, survival, and differentiation. Recently, it was reported that MCF10A, BT474, and MDA-MB-231 cells bearing the HER2 K753E mutation were
Egle Avizienyte et al.
The Biochemical journal, 415(2), 197-206 (2008-07-01)
Recent clinical data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance
查看所有相关文献

全球贸易项目编号

货号GTIN
SML2259-50MG04061835504947
SML2259-10MG04061835504930